c-Met/HGFR
Les inhibiteurs de c-Met/HGFR ciblent le Récepteur du Facteur de Croissance des Hépatocytes (c-Met), une tyrosine kinase impliquée dans des processus cellulaires tels que la croissance, la motilité et la morphogenèse. La signalisation de c-Met est impliquée dans la progression du cancer, la métastase et la résistance aux thérapies. Inhiber c-Met peut perturber la croissance et la propagation des tumeurs, faisant de ces inhibiteurs des outils précieux dans la recherche sur le cancer. Chez CymitQuimica, nous proposons des inhibiteurs de c-Met/HGFR pour soutenir vos recherches en oncologie, métastase et thérapies ciblées contre le cancer.
143 produits trouvés pour "c-Met/HGFR"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
Pamufetinib
CAS :Pamufetinib (TAS-115) is a potent inhibitor of VEGFR and hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase.Formule :C27H23FN4O4SDegré de pureté :99.39%Couleur et forme :SolidMasse moléculaire :518.56Ref: TM-T13108
1mg52,00€5mg101,00€10mg149,00€25mg244,00€50mg359,00€100mg510,00€200mg695,00€1mL*10mM (DMSO)127,00€Emibetuzumab
CAS :Emibetuzumab: potent humanized MET antibody, antitumor, inhibits HGF/MET pathways, for advanced prostate cancer research.Degré de pureté :SDS-PAGE:96.2%;SEC-HPLC:98.8%Couleur et forme :LiquidMasse moléculaire :143.74 kDaRilotumumab
CAS :Rilotumumab (AMG 102) is an HGF-targeting antibody, inhibits HGF/MET signaling, and is used for CRPC and gastric cancer research.
Degré de pureté :SDS-PAGE:95% SEC-HPLC:97.51%Couleur et forme :LiquidMasse moléculaire :145.2 kDaSU 5616
CAS :SU 5616 (WAY-608241) regulates abnormal cell proliferation and modulates tyrosine kinase signaling.
Formule :C13H8ClNOSDegré de pureté :98.84%Couleur et forme :SoildMasse moléculaire :261.73Bozitinib
CAS :Bozitinib (PLB-1001) (PLB-1001) is a highly selective inhibitor of the c-MET kinase with blood-brain barrier permeability.Formule :C20H15F3N8Degré de pureté :99.16%Couleur et forme :SolidMasse moléculaire :424.38Ref: TM-T10585
1mg92,00€5mg205,00€10mg334,00€25mg595,00€50mg858,00€100mg1.198,00€200mg1.611,00€1mL*10mM (DMSO)227,00€CSF1R-IN-2
CAS :CSF1R-IN-2 is an oral-active SRC, MET and c-FMS inhibitor (IC50s: 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively).Formule :C20H20FN7O2Degré de pureté :99.29%Couleur et forme :SolidMasse moléculaire :409.42JNJ-38877618
CAS :JNJ-38877618 (OMO-1) is an effective and highly selective inhibitor of Met kinase (IC50s: 2 and 3 nM for wild type and mutant Met, respectively).Formule :C20H12F2N6Degré de pureté :98.84% - 99.74%Couleur et forme :SolidMasse moléculaire :374.35Ref: TM-T15617
1mg59,00€5mg130,00€10mg200,00€25mg401,00€50mg557,00€100mg737,00€1mL*10mM (DMSO)144,00€Onartuzumab
CAS :Onartuzumab (MetMAb) is a humanized monoclonal antibody targeting c-MET, with antitumor effects by blocking HGF and signal transduction.Degré de pureté :97.3%Couleur et forme :LiquidMasse moléculaire :146.99 kDac-Met inhibitor 1
CAS :c-Met inhibitor 1 is a c-Met receptor signaling pathway inhibitor, used for the treatment of cancer including glioblastoma, gastric, and pancreatic cancer.Formule :C17H14N8SDegré de pureté :98.77%Couleur et forme :SolidMasse moléculaire :362.41C-Met inhibitor D9
CAS :C-Met inhibitor D9 is a c-Met kinase inhibitor.Formule :C17H15N3O2Degré de pureté :97.45%Couleur et forme :SolidMasse moléculaire :293.32PROTAC c-Met degrader-2
CAS :PROTACc-Met degrader-2 (PROTAC2) is a c-Met degrader developed using PROTAC technology, with a DC50 value of 50 nM.Formule :C51H50F2N6O13Couleur et forme :SolidMasse moléculaire :992.97PROTAC c-Met degrader-3
PROTACc-Met degrader-3 (Compound 22b) is a c-Met PROTAC degrader. It facilitates the ubiquitination and degradation of c-Met, with a DC50 of 0.59 nM in EBC-1 cells. PROTACc-Met degrader-3 is applicable in lung cancer research.Formule :C51H54N10O7Couleur et forme :SolidMasse moléculaire :919.037PF-04217903 phenolsulfonate
CAS :PF-04217903 phenolsulfonate is a potent ATP-competitive inhibitor of c-Met kinase (Ki of 4.8 nM for human c-Met).Formule :C25H22N8O5SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :546.56PROTAC c-Met degrader-1
CAS :PROTACc-Met degrader-1 (Compound Met-DD4) is an orally effective PROTAC degrader targeting c-Met with a DC50 of 6.21 nM. It inhibits the proliferation of c-Met-addicted MKN-45 cells with an IC50 of 4.37 nM and causes cell cycle arrest in the G0/G1 phase. In a xenograft mouse model using MKN-45 cells, PROTACc-Met degrader-1 demonstrates antitumor activity.Formule :C45H41FN10O5Couleur et forme :SolidMasse moléculaire :820.87c-Met ligand-Linker Conjugate 1
c-Met ligand-Linker Conjugate 1 is a Target Protein Ligand-Linker Conjugate that consists of a c-Met ligand and a PROTAC linker, capable of recruiting E3 ligase. This compound is used in the synthesis of PROTACc-Met degrader-5.Couleur et forme :Odour SolidLMTK3-IN-1
CAS :Lmtk3-in-1 is a potent ATP-competitive lemur tyrosine kinase 3 (LMTK3) (Kd=2.5 μM) inhibitor that degrades LMTK3 through the ubiquitin proteasome pathway.Formule :C18H11F3N4ODegré de pureté :99.58%Couleur et forme :SoildMasse moléculaire :356.3Norleual
CAS :Angiotensin IV analog, potent HGF/c-MET inhibitor (IC50=3 pM), halts MDCK cell growth and invasion, AT4 antagonist, impairs LTP, antiangiogenic.
Formule :C41H58N8O7Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :774.95c-Met-IN-19
c-Met-IN-19 (Compound 21j) is a potent c-Met inhibitor with an IC50 of 1.99 nM and demonstrates cytotoxic effects on various cancer cell lines, including A549,Formule :C34H37Cl2FN4O7SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :735.65Narnatumab
CAS :Narnatumab (IMC-RON8) is a humanized antibody targeting the macrophage-stimulating receptor (RON) with antitumor activity, used in advanced malignant solid tumors research.Degré de pureté :>95%Couleur et forme :LiquidMasse moléculaire :145.8 kDaUmikibart
Umikibart is a humanized IgG4κ antibody targeting HGF, with the corresponding isotype control being HumanIgG4(S228P) kappa, Isotype Control.Couleur et forme :Odour LiquidFosgonimeton acetate
Fosgonimeton acetate is an agonist of hepatocyte growth factor (HGF).Formule :C29H49N4O10PDegré de pureté :98.01%Couleur et forme :SolidMasse moléculaire :644.69Ref: TM-T39507L
1mg116,00€2mg160,00€5mg238,00€10mg353,00€25mg563,00€50mg758,00€100mg1.017,00€200mg1.359,00€CE-355621
CE-355621 is a humanized anti-c-Met IgG1 monoclonal antibody. It effectively binds to human c-Met in A549 cells (KD= 200 pM, IC50= 466 pM) and also binds effectively to c-Met in cynomolgus monkey kidney cells (KD= 610 pM). CE-355621 inhibits the c-Met signaling pathway by blocking HGF binding and significantly suppresses tumor growth dependent on the c-Met/HGF pathway. It is applicable for research in cancers such as glioblastoma and gastric cancer.c-Met-IN-17
c-Met-IN-17 is a potent inhibitor of c-Met kinase, demonstrating an IC50 of 0.031 μM, and is applicable in anticancer research. [1]Formule :C21H15FN4O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :374.37Telisotuzumab
CAS :Telisotuzumab(ABT-700) is a humanized recombinant antibody targeting the therapeutic hepatocyte growth factor receptor (MET) with high affinity for c-Met.
Degré de pureté :SDS-PAGE:96.4%;SEC-HPLC:98.5%Couleur et forme :LiquidMasse moléculaire :145.50 kDa1D228
1D228, a c-Met/TRK inhibitor with antitumor properties, suppresses cyclin D1 to precipitate G0/G1 arrest, thereby inhibiting proliferation and migration ofDegré de pureté :98%Couleur et forme :Odour SolidCaveolin-1 (82-101) amide (human, mouse, rat)
CAS :Caveolin-1 (82-101) amide (human, mouse, rat), also known as Caveolin-1 scaffolding domain peptide, mitigates aging-related detrimental alterations in variousFormule :C124H170N28O29Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :2516.85BMS-777607
CAS :BMS-777607 is a Met-related inhibitor for c-Met, Axl, Ron and Tyro3.Formule :C25H19ClF2N4O4Degré de pureté :98.16% - 98.56%Couleur et forme :SolidMasse moléculaire :512.89Ref: TM-T2658
2mg59,00€5mg86,00€10mg135,00€25mg251,00€50mg388,00€100mg690,00€200mg1.034,00€500mg1.550,00€c-Met-IN-18
C-Met-IN-18, an ATP-competitive type-III inhibitor, targets both wild-type (WT) and D1228V mutant c-MET with IC50 values of 0.013 µM and 0.20 µM, respectively.Formule :C21H15FN4O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :374.37Antitumor agent-111
Antitumor Agent-111 (Compound 46), a c-Met kinase inhibitor (IC50 = 46 nM), exhibits both antitumor and antiproliferative effects.Formule :C34H29ClF2N6O5Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :675.08c-Met-IN-23
c-Met-IN-23 (Compound 12g) functions as a c-Met inhibitor with an IC50 of 0.052 μM against c-Met. It also inhibits the MDR1 and MRP1/2 pumps in cancerous HepG2 and BxPC3 cells. As such, c-Met-IN-23 serves as an anticancer agent.Formule :C16H13N7OMasse moléculaire :319.11816SYN1143
CAS :SYN1143 (AMG-1) strongly inhibits RON & c-Met with IC50s: 9 & 4 nmol/L.Formule :C31H29FN4O5Degré de pureté :99.69%Couleur et forme :SolidMasse moléculaire :556.58PF-04217903 methanesulfonate
CAS :PF-04217903 methanesulfonate is a potent ATP-competitive inhibitor of c-Met kinase (Ki of 4.8 nM for human c-Met).Formule :C20H20N8O4SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :468.49Norleual TFA
Norleual TFA, Ang IV analog, inhibits HGF/c-Met (IC50: 3 pM), blocks AT4, and has strong antiangiogenic effects.Formule :C43H59F3N8O9Masse moléculaire :888.97S49076 HCl
CAS :S49076 HCl (S-49076 Hydrochloride) is an effective inhibitor of MET, AXL/MER, and FGFR1/2/3.Formule :C22H18ClN3O5Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :439.85SAR125884 hydrochlorid (1116743-46-4(free base))
CAS :SAR125844 is a potent and selective MET kinase inhibitor with a favorable preclinical toxicity profile,(IC50=4.2 nM).Formule :C25H23FN8O2S2·HClDegré de pureté :97.95%Couleur et forme :SolidMasse moléculaire :587Ref: TM-T5677
1mg35,00€5mg57,00€10mg95,00€25mg178,00€50mg264,00€100mg374,00€200mg537,00€1mL*10mM (DMSO)96,00€NPS-1034
CAS :NPS-1034 is a dual Met/Axl inhibitor with IC50 of 48 nM and 10.3 nM, respectively.Formule :C31H23F2N5O3Degré de pureté :98.48%Couleur et forme :SolidMasse moléculaire :551.54Ref: TM-T6907
1mg34,00€2mg46,00€5mg66,00€10mg92,00€25mg167,00€50mg245,00€100mg356,00€200mg530,00€1mL*10mM (DMSO)82,00€PF-04217903
CAS :MET Tyrosine Kinase Inhibitor PF-04217903 is an orally bioavailabe, small-molecule tyrosine kinase inhibitor with potential antineoplastic activity.Formule :C19H16N8ODegré de pureté :98.41% - 98.55%Couleur et forme :SolidMasse moléculaire :372.38CEP-40783
CAS :CEP-40783 (RXDX-106) is an effective, specific and orally active AXL/c-Met inhibitor (IC50: 7/12 nM). It also inhibits MER and TYRO3 (IC50: 29/19 nM).
Formule :C31H26F2N4O6Degré de pureté :99.76% - 99.84%Couleur et forme :SolidMasse moléculaire :588.56Ningetinib Tosylate
CAS :Ningetinib Tosylate is an orally bioavailable tyrosine kinase inhibitor with IC50s of <1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively.Formule :C38H37FN4O8SDegré de pureté :99.93%Couleur et forme :SolidMasse moléculaire :728.79Crizotinib
CAS :Crizotinib (PF-02341066) is an ATP-competitive small-molecule tyrosine kinases inhibitor of c-MET (IC50: 8 nM) and ALK (IC50: 20 nM) receptor.Formule :C21H22Cl2FN5ODegré de pureté :99% - 99.87%Couleur et forme :SolidMasse moléculaire :450.34Ref: TM-T1661
2mgÀ demander5mg33,00€10mg49,00€25mg55,00€50mg64,00€100mg88,00€500mg147,00€1mL*10mM (DMSO)50,00€AMG-208
CAS :AMG-208 is a highly selective c-Met inhibitor with IC50 of 9 nM. Phase 1.Formule :C22H17N5O2Degré de pureté :98.56%Couleur et forme :SolidMasse moléculaire :383.4S49076
CAS :S49076 is a novel, potent inhibitor of MET, AXL/MER, and FGFR1/2/3, blocking cellular phosphorylation of MET, AXL, and FGFRs.Formule :C22H22N4O4SDegré de pureté :95.35% - 97.4%Couleur et forme :SolidMasse moléculaire :438.5Ref: TM-T3274
1mg34,00€2mg44,00€5mg58,00€10mg93,00€25mg167,00€50mg260,00€100mg432,00€200mg618,00€1mL*10mM (DMSO)64,00€DS-1205
CAS :DS-1205: AXL kinase inhibitor (IC50=1.3 nM), also targets MER, MET, TRKA (IC50s: 63, 104, 407 nM), hinders cell migration and tumor growth.Formule :C41H42FN5O7Degré de pureté :99.75%Couleur et forme :SolidMasse moléculaire :735.8Capmatinib 2HCl
CAS :Capmatinib 2HCl (INC-280 2HCl), a c-MET inhibitor, is potent (IC50 = 0.13 nM), highly specific, and induces apoptosis in tumor cells.Formule :C23H19Cl2FN6ODegré de pureté :98.80%Couleur et forme :SolidMasse moléculaire :485.34Ref: TM-T4260
2mg34,00€5mg49,00€10mg64,00€25mg84,00€50mg92,00€100mg126,00€500mg303,00€1mL*10mM (DMSO)58,00€SGX-523
CAS :SGX-523 is a selective Met inhibitor (IC50: 4 nM), no inhibitory to Abl, BRAFV599E, p38α, and c-Raf.
Formule :C18H13N7SDegré de pureté :99% - >99.99%Couleur et forme :SolidMasse moléculaire :359.41PHA-665752
CAS :PHA-665752 is an effective, specific and ATP-competitive c-Met inhibitor (IC50: 9 nM), >50-fold selectivity for c-Met than STKs or RTKs.Formule :C32H34Cl2N4O4SDegré de pureté :97.05% - 98.82%Couleur et forme :SolidMasse moléculaire :641.61Amuvatinib
CAS :Amuvatinib (MP470) is an orally bioavailable synthetic carbothioamide with potential antineoplastic activity.Formule :C23H21N5O3SDegré de pureté :99.38% - >99.99%Couleur et forme :SolidMasse moléculaire :447.51BMS-794833
CAS :BMS-794833 is a potent ATP competitive inhibitor of Met/VEGFR2; a prodrug of BMS-817378.Formule :C23H15ClF2N4O3Degré de pureté :98% - 99.69%Couleur et forme :SolidMasse moléculaire :468.84Capmatinib
CAS :Capmatinib (INCB28060) is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity.Formule :C23H17FN6ODegré de pureté :99.24%Couleur et forme :SolidMasse moléculaire :412.42Ref: TM-T1963
5mg48,00€10mg63,00€25mg78,00€50mg90,00€100mg124,00€200mg158,00€500mg255,00€1mL*10mM (DMSO)50,00€Afatinib Dimaleate
CAS :Afatinib Dimaleate (BIBW 2992MA2) is an orally bioavailable anilino-quinazoline derivative and inhibitor of the EGFR family, with antineoplastic activity.Formule :C32H33ClFN5O11Degré de pureté :98.11% - 99.87%Couleur et forme :SolidMasse moléculaire :718.08c-Kit-IN-1
CAS :c-Kit-IN-1 (DCC-2618) is an effective inhibitor of c-Met and c-Kit (IC50s<200 nM).Formule :C26H21F2N5O3Degré de pureté :98.72% - 98.73%Couleur et forme :SolidMasse moléculaire :489.47Ref: TM-T4332
1mg39,00€5mg81,00€10mg120,00€25mg235,00€50mg373,00€100mg610,00€200mg840,00€1mL*10mM (DMSO)88,00€X-376
CAS :X-376 (Ensartinib) is an orally available small molecule inhibitor of the receptor tyrosine kinase ALK with potential antineoplastic activity.Formule :C25H25Cl2FN6O3Degré de pureté :97.87%Couleur et forme :SolidMasse moléculaire :547.41Ref: TM-T3550
1mg35,00€2mg50,00€5mg87,00€10mg119,00€25mg258,00€50mg427,00€100mg582,00€1mL*10mM (DMSO)105,00€BMS817378
CAS :BMS817378 is a potent and selective inhibitor of MET(IC50 : 1.7 nM).Formule :C24H18ClF2N4O7PDegré de pureté :>99.99%Couleur et forme :SolidMasse moléculaire :578.85Ensartinib hydrochloride
CAS :Ensartinib hydrochloride (X-396 dihydrochloride) is a potent new-generation ALK inhibitor with high activity against CNS metastases and a broad range of knownFormule :C26H29Cl4FN6O3Degré de pureté :98.73%Couleur et forme :SolidMasse moléculaire :634.36Ref: TM-T22324
1mg54,00€5mg114,00€10mg177,00€25mg356,00€50mg580,00€100mg888,00€1mL*10mM (DMSO)158,00€Glumetinib
CAS :Glumetinib (SCC244) (SCC 244) is a novel potent and selective inhibitor of c-Met kinase (IC50: 0.42 nM).
Formule :C21H17N9O2SDegré de pureté :99.79%Couleur et forme :SolidMasse moléculaire :459.48Hepln-13
CAS :Hepln-13 is a hepsin inhibitor that acts by hindering prostate cancer bone metastasis.Formule :C17H13BrN2Degré de pureté :97.67%Couleur et forme :SolidMasse moléculaire :325.2Ref: TM-T25492
1mg35,00€2mg52,00€5mg80,00€10mg119,00€25mg231,00€50mg344,00€100mg480,00€200mg663,00€1mL*10mM (DMSO)92,00€Altiratinib
CAS :Altiratinib (DCC-2701)(DCC-2701) is a novel c-MET/TIE-2/VEGFR inhibitor; effectively reduce tumor burden in vivo and block c-MET pTyr(1349)-mediated signaling,Formule :C26H21F3N4O4Degré de pureté :99.67% - 99.75%Couleur et forme :SolidMasse moléculaire :510.46NVP-BVU972
CAS :NVP-BVU972 is a selective and potent Met inhibitor with IC50 of 14 nM.Formule :C20H16N6Degré de pureté :97.24% - >99.99%Couleur et forme :SolidMasse moléculaire :340.38Ref: TM-T2680
2mg44,00€5mg74,00€10mg97,00€25mg178,00€50mg255,00€100mg359,00€200mg510,00€1mL*10mM (DMSO)84,00€BMS 777607
CAS :BMS 777607 (BMS 817378) is a Met-related inhibitor for c-Met/Axl/Ron/Tyro3. BMS-777607 has been investigated for the basic science of Malignant Solid Tumour.Formule :C25H19ClF2N4O4Degré de pureté :98.89% - >99.99%Couleur et forme :SolidMasse moléculaire :512.89Ref: TM-T2699
1mg35,00€5mg79,00€10mg124,00€25mg217,00€50mg359,00€100mg533,00€500mg1.169,00€1mL*10mM (DMSO)92,00€MK-8033
CAS :MK-8033 is a new and selective dual ATP competitive c-Met/Ron inhibitor (IC50: 1 nM Wt c-Met).Formule :C25H21N5O3SDegré de pureté :97.16%Couleur et forme :SolidMasse moléculaire :471.53Golvatinib
CAS :Golvatinib (E-7050) is an orally bioavailable dual kinase inhibitor of c-Met (hepatocyte growth factor receptor) and VEGFR-2 (vascular endothelial growth factorFormule :C33H37F2N7O4Degré de pureté :98.24% - ≥95%Couleur et forme :SolidMasse moléculaire :633.69Ref: TM-T6517
1mgÀ demander2mg46,00€5mg66,00€10mg92,00€25mg149,00€50mg197,00€100mg350,00€1mL*10mM (DMSO)À demanderAMG-337
CAS :AMG-337 is an effective and highly specific ATP-competitive MET kinase inhibitor. In enzymatic assays, AMG-337 inhibits MET kinase activity (IC50: < 5 nM).Formule :C23H22FN7O3Degré de pureté :99.26% - 99.9%Couleur et forme :SolidMasse moléculaire :463.46Ref: TM-T3209
1mg40,00€2mg52,00€5mg85,00€10mg124,00€25mg197,00€50mg350,00€100mg522,00€200mg748,00€1mL*10mM (DMSO)86,00€Capmatinib 2HCl.H2O
CAS :Capmatinib 2HCl.H2O (NVP-INC280 2HCl.H2O) is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity.Formule :C23H21Cl2FN6O2Degré de pureté :99.77%Couleur et forme :SolidMasse moléculaire :503.36Ref: TM-T8825
2mg34,00€5mg48,00€10mg63,00€25mg84,00€50mg92,00€100mg126,00€500mg250,00€1mL*10mM (DMSO)50,00€Foretinib
CAS :Foretinib (GSK1363089) is a broad-spectrum tyrosine kinase inhibitor with IC50s of 0.4 nM and 0.9 nM for Met and KDR.Formule :C34H34F2N4O6Degré de pureté :98.07% - 99.68%Couleur et forme :SolidMasse moléculaire :632.65Ref: TM-T3113
2mg39,00€5mg57,00€10mg79,00€25mg133,00€50mg207,00€100mg354,00€500mg848,00€1mL*10mM (DMSO)79,00€Ningetinib
CAS :Ningetinib (CT-053) (CT053PTSA) is an orally bioavailable tyrosine kinase inhibitor with IC50s of <1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively.Formule :C31H29FN4O5Degré de pureté :99.95% - 99.98%Couleur et forme :SolidMasse moléculaire :556.58Afatinib
CAS :Afatinib (BIBW 2992) is an irreversible and orally EGFR family inhibitor that inhibits EGFR and HER2. Afatinib has antitumor activity. Cost effective and quality assured.
Formule :C24H25ClFN5O3Degré de pureté :98.56% - 99.9%Couleur et forme :Off-White SolidMasse moléculaire :485.94BAY-474
CAS :BAY-474 is an inhibitor of tyrosine-protein kinase c-Met. It acts as an epigenetics probeFormule :C17H15N5Degré de pureté :98.98%Couleur et forme :SolidMasse moléculaire :289.33Ref: TM-T7900
1mg35,00€5mg71,00€10mg112,00€25mg203,00€50mg294,00€100mg411,00€200mg553,00€1mL*10mM (DMSO)84,00€Crizotinib hydrochloride
CAS :Crizotinib hydrochloride (PF-02341066 hydrochloride) is a novel inhibitor of anaplastic lymphoma kinase and c-Met(IC50s of 20 and 8 nM)Formule :C21H23Cl3FN5ODegré de pureté :98.73% - 98.87%Couleur et forme :SolidMasse moléculaire :486.8Ref: TM-T8399
5mg34,00€10mg50,00€25mg78,00€50mg94,00€100mg131,00€200mg162,00€500mg215,00€1mL*10mM (DMSO)56,00€Cabozantinib hydrochloride
CAS :Cabozantinib hydrochloride (XL184) is a potent pan-tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt4 (IC50s: 0.035, 1.3, 4.6, 7 and 6Formule :C28H25ClFN3O5Degré de pureté :99.97%Couleur et forme :SolidMasse moléculaire :537.96Ref: TM-T5164
1mg42,00€2mg52,00€5mg65,00€10mg92,00€25mg160,00€50mg235,00€100mg330,00€200mg538,00€500mg860,00€(Z)-Semaxinib
CAS :(Z)-Semaxinib (SU5416) is a potent and selective VEGFR(Flk-1/KDR) inhibitor (IC50: 1.23 μM), 20-fold more selective for VEGFR over PDGFRβ, no inhibition forFormule :C15H14N2ODegré de pureté :98.82% - ≥95%Couleur et forme :SolidMasse moléculaire :238.28Ref: TM-T2496
10mg35,00€25mg52,00€50mg79,00€100mg111,00€200mg168,00€500mg330,00€1mL*10mM (DMSO)44,00€Cabozantinib
CAS :Cabozantinib (XL184) is a multi-targeted tyrosine kinase receptor inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt3 (IC50=0.035/1.3/4.6/7/11.3 nM).
Formule :C28H24FN3O5Degré de pureté :99.68% - 99.88%Couleur et forme :SolidMasse moléculaire :501.51SRI 31215 TFA
CAS :SRI 31215 TFA acts as a triplex inhibitor of matriptase, hepsin and HGFA and mimics the activity of HAI-1/2, endogenous inhibitors of HGF activation.Formule :C27H34F3N5O3Degré de pureté :98.25% - 99.97%Couleur et forme :SolidMasse moléculaire :533.6Ref: TM-T5478
1mg40,00€5mg92,00€10mg128,00€25mg248,00€50mg370,00€100mg527,00€200mg713,00€1mL*10mM (DMSO)96,00€Capmatinib xHCl
CAS :Capmatinib xHCl (INCB28060) is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor, potently blocking in vitro kinase activity (IC50Formule :C23H18ClFN6ODegré de pureté :98.62% - 99.81%Couleur et forme :SolidMasse moléculaire :448.89Merestinib dihydrochloride
CAS :Merestinib dihydrochloride (LY2801653 dihydrochloride) is a kinase inhibitor with antitumor activity that inhibits MET and MKNK1/2.Formule :C30H24Cl2F2N6O3Couleur et forme :SolidMasse moléculaire :625.45Savolitinib
CAS :Savolitinib (Volitinib) (AZD-6094) is an effective, selective, and orally bioavailable c-Met inhibitor (IC50s: 5 nM/3 nM for c-Met/p-Met).Formule :C17H15N9Degré de pureté :98.12%Couleur et forme :SolidMasse moléculaire :345.36Ref: TM-TQ0210
1mg47,00€2mg60,00€5mg96,00€10mg124,00€25mg200,00€50mg353,00€100mg537,00€1mL*10mM (DMSO)92,00€MGCD-265 analog
CAS :Glesatinib, an oral tyrosine kinase inhibitor, targets c-Met and VEGFR2 with IC50s of 29 nM and 10 nM, may treat cancer.Formule :C26H20FN5O2S2Degré de pureté :98.06% - 98.68%Couleur et forme :SolidMasse moléculaire :517.6Merestinib
CAS :Merestinib (LY2801653) is an orally available, small molecule inhibitor of the proto-oncogene c-Met (Ki: 2 nM) with potential antineoplastic activity.Formule :C30H22F2N6O3Degré de pureté :95% - 99.71%Couleur et forme :SolidMasse moléculaire :552.53Ref: TM-T3455
1mg50,00€2mg66,00€5mg100,00€10mg137,00€25mg240,00€50mg403,00€100mg573,00€500mg1.198,00€1mL*10mM (DMSO)119,00€Tivantinib
CAS :Tivantinib (ARQ 197) is an orally bioavailable small molecule inhibitor of c-Met with potential antineoplastic activity.Formule :C23H19N3O2Degré de pureté :98% - 99.41%Couleur et forme :SolidMasse moléculaire :369.42RPI-1
CAS :RPI-1 is a competitive, potent ATP-dependent Ret kinase inhibitor.Formule :C17H15NO4Degré de pureté :98.91% - ≥95%Couleur et forme :SolidMasse moléculaire :297.31SGI-7079
CAS :SGI-7079: selective Axl inhibitor; hinders tumor growth dose-dependently; may target EGFR inhibitor resistance.Formule :C26H26FN7Degré de pureté :95.51% - 99.26%Couleur et forme :SolidMasse moléculaire :455.53Ref: TM-T6982
2mg39,00€5mg58,00€10mg92,00€25mg178,00€50mg230,00€100mg334,00€500mg782,00€1mL*10mM (DMSO)64,00€JNJ-38877605
CAS :JNJ-38877605 is an ATP-competitive c-Met inhibitor (IC50: 4 nM), 600-fold selective for c-Met than 200 other tyrosine and serine-threonine kinases.Formule :C19H13F2N7Degré de pureté :97.15% - 98.61%Couleur et forme :SolidMasse moléculaire :377.35BMS-2
CAS :BMS-2 is a Met/Flt-3/VEGFR2 tyrosine kinase inhibitor.Formule :C25H16F2N4O3Degré de pureté :98.33%Couleur et forme :SolidMasse moléculaire :458.42Ref: TM-T8326
1mg67,00€2mg88,00€5mg148,00€10mg230,00€25mg430,00€50mg622,00€100mg898,00€1mL*10mM (DMSO)170,00€XL092
CAS :XL092 (JUN04542) is an Axl Mer cMet KDR inhibitor for the treatment of Axl and Mer receptor tyrosine kinase- dependent disorders.
Formule :C29H25FN4O5Degré de pureté :98.60%Couleur et forme :SolidMasse moléculaire :528.53SCR-1481B1
CAS :SCR-1481B1 (c-Met inhibitor 2) has activity against cancers dependent on Met activation and also has activity against cancers as a VEGFR inhibitorFormule :C32H40ClF2N6O13PDegré de pureté :98.07%Couleur et forme :SolidMasse moléculaire :821.12Ref: TM-T5349
1mg35,00€2mg50,00€5mg74,00€10mg113,00€25mg200,00€50mg333,00€100mg495,00€1mL*10mM (DMSO)102,00€Pamufetinib mesylate
CAS :Pamufetinib mesylate (TAS-115 mesylate) is a VEGFR antagonist and c-Met inhibitor used in the study of cancer and respiratory diseases.Formule :C28H27FN4O7S2Degré de pureté :98.91%Couleur et forme :SolidMasse moléculaire :614.67Foretinib phosphate
CAS :Foretinib phosphate, an oral MET/VEGFR2 inhibitor GSK1363089, may curb tumor growth and spread.Formule :C34H40F2N4O14P2Couleur et forme :SolidMasse moléculaire :828.65Amivantamab (Anti-c-MET)
CAS :Amivantamab (JNJ-61186372) is an antibody that recognizes EGFR and MET and has anticancer and antitumor activities.Degré de pureté :97.24% (SEC-HPLC) - >95.0% (SDS-PAGE); 99.74% (SEC-HPLC)Couleur et forme :LiquidMasse moléculaire :145.88 kDaDavutamig
CAS :Davutamig (REGN-5093) is a humanized IgG4-kappa, anti-MET monoclonal antibody that binds to two distinct, nonoverlapping epitopes on the MET receptor.Degré de pureté :98%Couleur et forme :LiquidBafisontamab
CAS :Bafisontamab (EMB-01) is a bispecific antibody that targets EGFR and cMET, displaying antitumor activity [1].Couleur et forme :LiquidMAPK-IN-2
MAPK-IN-2 (compound 3h) is an efficacious MAPK inhibitor with antineoplastic properties that significantly hinders proliferation across various cancer cellFormule :C20H11Cl2N3ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :380.23BMS-754807
CAS :BMS-754807 is an oral IGF-1R/InsR inhibitor with potential anti-cancer properties.Formule :C23H24FN9ODegré de pureté :99.69% - 99.94%Couleur et forme :SolidMasse moléculaire :461.49Ref: TM-T2349
1mg50,00€2mg66,00€5mg90,00€10mg158,00€25mg310,00€50mg509,00€100mg732,00€1mL*10mM (DMSO)110,00€SU11274
CAS :SU11274 (Met Kinase Inhibitor)(IC50=10 nM) is a specific Met inhibitor. It shows no significant effects on PGDFRβ, EGFR or Tie2.Formule :C28H30ClN5O4SDegré de pureté :98.62% - 99.53%Couleur et forme :Orange PowderMasse moléculaire :568.09Ref: TM-T6154
1mg44,00€2mg56,00€5mg92,00€10mg142,00€25mg268,00€50mg442,00€100mg652,00€1mL*10mM (DMSO)142,00€AMG-458
CAS :AMG-458 is a potent c-Met inhibitor with Ki of 1.2 nM, ~350-fold selectivity for c-Met than VEGFR2 in cells.Formule :C30H29N5O5Degré de pureté :99.91% - 99.98%Couleur et forme :SolidMasse moléculaire :539.58Glesatinib hydrochloride
CAS :Glesatinib hydrochloride is an orally active and potent dual inhibitor of MET/SMO.Formule :C31H28ClF2N5O3S2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :656.16Glesatinib
CAS :Glesatinib is an orally active and potent dual inhibitor of MET/SMO.Formule :C31H27F2N5O3S2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :619.7AC-386
CAS :AC-386, a potent c-Met inhibitor (IC50 7.42 nM), inhibits cancer cell growth and aids anti-cancer resistance study.Formule :C35H34FN5O6Couleur et forme :SolidMasse moléculaire :639.67LCRF-0004
CAS :LCRF-0004 inhibits RON kinase, key in KRAS-driven pancreatic cancer, reducing cell migration and enhancing chemo sensitivity.Formule :C28H18F4N6O2SCouleur et forme :SolidMasse moléculaire :578.54c-Met-IN-11
CAS :c-Met-IN-11 is a potent inhibitor of c-MET (IC50: 41.4 nM) and VEGFR-2 (IC50: 71.1 nM).Formule :C30H20F2N4O3Couleur et forme :SolidMasse moléculaire :522.5Axl-IN-8
CAS :Axl-IN-8 (NO.1) is a potent inhibitor of AXL (IC50<1 nM) and also inhibits c-MET (IC50: 1-10 nM). : 120.3 nM).Formule :C31H29FN6O3Couleur et forme :SolidMasse moléculaire :552.6Mifanertinib
CAS :Mifanertinib is a potent tyrosine kinase inhibitor with antineoplastic activity .Formule :C21H19ClF3N5O2Couleur et forme :SolidMasse moléculaire :465.86
